UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.

Werewolf Therapeutics, a US-based cancer biotherapeutics developer, completed a $72m series B round on Thursday backed by UPMC Enterprises, the investment arm of healthcare provider University of Pittsburgh Medical Center (UPMC). RA Capital Management led the round, while healthcare investment firm Deerfield Management and Taiho Ventures, the corporate venturing division of pharmaceutical firm Taiho Pharmaceutical,…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.